Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI.
Ontology highlight
ABSTRACT: Triple anti-thrombotic therapy combining oral anticoagulation and dual anti-platelet therapy following percutaneous coronary intervention in patients with atrial fibrillation was considered as standard and recommended by guidelines. While bleeding risk is considerable with that approach, data for efficacy are scare. Several trials assessed the possibility of reducing anti-thrombotic treatment by mainly shortening the exposure to acetylsalicylic acid. Dropping one of the anti-platelet components might increase the risk of stent thrombosis, myocardial infarction or stroke. Despite that fear, the recent trials' primary endpoint was major and/or clinically-relevant non-major bleeding. We review data on major bleedings, intracranial bleedings and major adverse cardiovascular events from the pub
SUBMITTER: Schafer A
PROVIDER: S-EPMC8166702 | biostudies-literature | 2021 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA